Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...

AstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecan December 09, 2024 — 05:30 am EST Written by TheFly for TipRanks -> ...

Following the U.S. approval, $45 million is due from AstraZeneca to Daiichi Sankyo Co., Ltd. DSKYF DSNKY as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca and Daiichi Sankyo's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. Provided by Dow Jones Jun 23, 2025, 11:33:00 PM ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) announced Tuesday they have withdrawn the EU marketing application for their experimental lung cancer therapy, datopotamab deruxtecan ...

Overview DSKYF Daiichi Sankyo Co Ltd $25.10 6.81 % DSNKY Daiichi Sankyo Co Ltd $24.21 -1.57 % On Monday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca plc and Daiichi Sankyo’s ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast cancer drug Dato-DXd. Read more here.